Settlement and Recall Impact Philips’ Financials
- Philips to halt CPAP sales in the U.S.
- Takes $393 million provision
- Settlement with U.S. Justice Department
- Recall of sleep therapy and respiratory machines
- Fourth-quarter profit of €38 million
- Sales fell 7% to €5.06 billion
- Expecting 3-5% sales growth this year
Philips announced that it will stop selling new sleep-therapy devices in the U.S. as part of a settlement with the U.S. Justice Department, resulting in a provision of $393 million. The company will continue to service existing machines and sell accessories. The provision covers remediation activities, inventory write-downs, and onerous contract provisions. Philips has faced recalls of millions of sleep therapy and respiratory machines due to foam breakdown and overheating risks. In its fourth-quarter financials, Philips reported a profit of €38 million, a 7% decline in sales to €5.06 billion, and a 3% decline in orders. However, the company expects 3-5% sales growth this year. The stock fell 5% in early Amsterdam trade but has gained 26% over the last 52 weeks. Analysts view the settlement as providing much-needed clarity.
Public Companies: Philips (PHIA)
Private Companies:
Key People:
Factuality Level: 7
Justification: The article provides information about Philips halting the sales of sleep-therapy devices in the U.S. due to a settlement with the U.S. Justice Department. It mentions the reason for the halt, which is the risk associated with the foam used in the devices. It also includes information about the financial impact on Philips and the expectations for future sales growth. However, the article lacks specific details about the settlement terms and the potential harm caused by the devices.
Noise Level: 3
Justification: The article provides relevant information about Philips halting the sales of sleep-therapy devices in the U.S. due to safety concerns. It mentions the reason for the halt, the settlement terms, and the impact on Philips’ financials. However, the article lacks in-depth analysis, scientific rigor, and actionable insights. It also contains some repetitive information and does not explore the consequences of the decision on those who use the devices.
Financial Relevance: Yes
Financial Markets Impacted: The sales halt of sleep-therapy devices by Philips in the U.S. may impact the company’s financial performance and stock value.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the financial impact of Philips halting the sales of sleep-therapy devices in the U.S. due to a settlement and provision. There is no mention of an extreme event.
www.marketwatch.com 
